Supernus ends UBS credit line ahead of Indivior merger
Supernus Pharmaceuticals, Inc. terminated its uncommitted demand revolving credit line with UBS Bank USA on October 20, 2026. The company filed a Form 8-K with the Securities and Exchange Commission on October 26, 2026, to report the termination of the material definitive agreement. The move is tied to the pending business combination between Supernus and Indivior Pharmaceuticals, Inc., governed by an Agreement and Plan of Merger dated August 1, 2026. The original UBS Credit Line Agreement was established on February 8, 2023. It provided an uncommitted, demand revolving line of credit secured by a pledge of a securities collateral account maintained with UBS Bank USA and related assets. Supernus stated that the termination occurred in anticipation of and in connection with the completion of the merger with Indivior. The company also cited its intention to enter into a new senior secured credit facility at the closing of the transaction. As of the termination date, there were no advances, letters of credit, or other borrowings or obligations outstanding under the UBS Credit Line. Supernus did not incur any early termination penalties in connection with ending the agreement. In connection with the termination, UBS Bank USA released its security interests in the collateral that had secured the credit line. Timothy C. Dec, Senior Vice President and Chief Financial Officer at Supernus Pharmaceuticals, signed the report on behalf of the registrant. The company is incorporated in Delaware and listed on The Nasdaq Stock Market LLC under the ticker symbol SUPN. Its principal executive offices are located at 9715 Key West Ave in Rockville, MD. The filing includes an exhibit consisting of the cover page formatted in Inline XBRL.
Supernus Pharmaceuticals, Inc. terminated its uncommitted demand revolving credit line with UBS Bank USA on October 20, 2026. The company filed a Form 8-K with the Securities and Exchange Commission on October 26, 2026, to report the termination of the material definitive agreement. The move is tied to the pending business combination between Supernus and Indivior Pharmaceuticals, Inc., governed by an Agreement and Plan of Merger dated August 1, 2026. The original UBS Credit Line Agreement was established on February 8, 2023. It provided an uncommitted, demand revolving line of credit secured by a pledge of a securities collateral account maintained with UBS Bank USA and related assets. Supernus stated that the termination occurred in anticipation of and in connection with the completion of the merger with Indivior. The company also cited its intention to enter into a new senior secured credit facility at the closing of the transaction. As of the termination date, there were no advances, letters of credit, or other borrowings or obligations outstanding under the UBS Credit Line. Supernus did not incur any early termination penalties in connection with ending the agreement. In connection with the termination, UBS Bank USA released its security interests in the collateral that had secured the credit line. Timothy C. Dec, Senior Vice President and Chief Financial Officer at Supernus Pharmaceuticals, signed the report on behalf of the registrant. The company is incorporated in Delaware and listed on The Nasdaq Stock Market LLC under the ticker symbol SUPN. Its principal executive offices are located at 9715 Key West Ave in Rockville, MD. The filing includes an exhibit consisting of the cover page formatted in Inline XBRL.